In a phase 2 trial of 122 patients with untreated metastatic colorectal cancer, FOLFOXIRI plus ramucirumab did not improve confirmed response vs FOLFIRI plus ramucirumab (60.3% vs 59.3%; OR 1.04, P=0.91). Secondary OS favoured FOLFIRI (median 32.6 vs 28.2 months).
RCTn = 122
Kito et al. Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)